Edgestream Partners L.P. Sells 58,230 Shares of AbbVie Inc. $ABBV

Edgestream Partners L.P. lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 88.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,402 shares of the company’s stock after selling 58,230 shares during the quarter. Edgestream Partners L.P.’s holdings in AbbVie were worth $1,610,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Litman Gregory Wealth Management LLC acquired a new position in AbbVie during the fourth quarter worth $28,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. acquired a new stake in AbbVie in the 4th quarter valued at $31,000. Finally, WestEnd Advisors LLC lifted its position in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

Shares of ABBV stock opened at $244.62 on Tuesday. The company has a fifty day moving average price of $239.67 and a two-hundred day moving average price of $224.25. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The stock has a market cap of $432.19 billion, a P/E ratio of 69.10, a P/E/G ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 466.39%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the business earned $2.97 EPS. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.12 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is currently 195.48%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ABBV shares. Bank of America increased their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Royal Bank Of Canada lifted their target price on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Finally, Citigroup raised their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $271.48.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported strong second-quarter results, with revenue up 10.2% year over year and adjusted earnings per share exceeding consensus estimates. Growth from Skyrizi, Rinvoq and neuroscience products helped offset the continuing decline of Humira. AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
• Positive Sentiment: Cantor Fitzgerald raised its AbbVie price target from $265 to $285 and maintained an “overweight” rating, reflecting confidence in the company’s growth outlook and pipeline.
• Positive Sentiment: New oncology opportunities could provide additional long-term growth. AbbVie’s telisotuzumab adizutecan is cited as an emerging targeted treatment in esophageal cancer, while the late-stage ABBV-706 trial is testing another potential therapy in small-cell lung cancer. Esophageal Cancer Market Outlook
• Neutral Sentiment: Analyst commentary remains broadly constructive, with some estimates suggesting shares could approach $300, supported by AbbVie’s dividend profile and the performance of newer growth products. AbbVie Quietly Solved Its Biggest Problem—Now What?
• Negative Sentiment: The Apogee Therapeutics acquisition is reducing projected 2026 earnings per share while increasing research and development costs. Although AbbVie raised its revenue outlook, the earnings dilution and weaker near-term guidance have prompted investor caution. ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.